Abstract

BackgroundAntiretroviral therapy (ART) can mitigate the morbidity and mortality caused by the human immunodeficiency virus (HIV). Successful development of ART can be accelerated by accurate structural and biochemical data on targets and their responses to inhibitors. One important ART target, HIV integrase (IN), has historically been studied in vitro in a modified form adapted to bacterial overexpression, with a methionine or a longer fusion protein sequence at the N-terminus. In contrast, IN present in viral particles is produced by proteolytic cleavage of the Pol polyprotein, which leaves a phenylalanine at the N-terminus (IN 1F). Inspection of available structures suggested that added residues on the N-terminus might disrupt proper protein folding and formation of multimeric complexes.ResultsWe purified HIV-1 IN 1F1–212 and solved its structure at 2.4 Å resolution, which showed extension of an N-terminal helix compared to the published structure of IN1–212. Full-length IN 1F showed increased in vitro catalytic activity in assays of coupled joining of the two viral DNA ends compared to two IN variants containing additional N-terminal residues. IN 1F was also altered in its sensitivity to inhibitors, showing decreased sensitivity to the strand-transfer inhibitor raltegravir and increased sensitivity to allosteric integrase inhibitors. In solution, IN 1F exists as monomers and dimers, in contrast to other IN preparations which exist as higher-order oligomers.ConclusionsThe structural, biochemical, and biophysical characterization of IN 1F reveals the conformation of the native HIV-1 IN N-terminus and accompanying unique biochemical and biophysical properties. IN 1F thus represents an improved reagent for use in integration reactions in vitro and the development of antiretroviral agents.

Highlights

  • Antiretroviral therapy (ART) can mitigate the morbidity and mortality caused by the human immunodeficiency virus (HIV)

  • We report a two-domain N-terminal domain (NTD)–Catalytic core domain (CCD) crystal structure of IN Integrase with native N-terminal phenylalanine (1F) that shows a continuous helical fold beginning with the backbone carbonyl of F1, in contrast to the existing IN ­GSHNTD–CCD structure [66]

  • IN Integrase with Gly-Ser-His preceding N-terminal phenylalanine (GSH) contains the three residues (G-S-H) that remain after thrombin cleavage, as used to determine the structure of IN ­GSHNTD–CCD (PDB: 1K6Y) [66], and IN Integrase with methionine preceding N-terminal phenylalanine (MF) contains an N-terminal methionine found in constructs commonly used for bacterial overexpression [61, 63, 64]

Read more

Summary

Introduction

Antiretroviral therapy (ART) can mitigate the morbidity and mortality caused by the human immunodeficiency virus (HIV). One important ART target, HIV integrase (IN), has historically been studied in vitro in a modified form adapted to bacterial overexpression, with a methionine or a longer fusion protein sequence at the N-terminus. Full-length IN 1F showed increased in vitro catalytic activity in assays of coupled joining of the two viral DNA ends compared to two IN variants containing additional N-terminal residues. Integrase (IN), the retroviral enzyme that catalyzes integration, is produced by proteolysis of the viral Gag-Pol polyprotein precursor by the virusencoded protease. The NTD adopts a zinc finger fold containing a conserved HHCC motif essential for activity [3,4,5]. The CCD contains a D,D-35-E motif which binds divalent metal ions within an RNase H-like fold that comprises the active site [6,7,8]. Dimers of each isolated domain have been observed [3, 8, 10,11,12]

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call